Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor IX (FIX) Levels in Hemophilia B Patients Receiving IDELVION

Fosser C.; Roberts J.; Tortorici M.; Jacobs I.; Sidhu J.

首页> 外文期刊>Journal of pharmacokinetics and pharmacodynamics >Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor IX (FIX) Levels in Hemophilia B Patients Receiving IDELVION

【24h】

Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor IX (FIX) Levels in Hemophilia B Patients Receiving IDELVION

机译：鉴定有关血友病患者的因子IX（修复）水平的有效阈值，血友病患者接受eteelvion的患者

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of pharmacokinetics and pharmacodynamics 》 |2017年第suppla期| 共1页
作者
Fosser C.; Roberts J.; Tortorici M.; Jacobs I.; Sidhu J.;
展开▼
作者单位

Cytel Cambridge MA USA;

CSL Behring King Of Prussia PA USA;

CSL Behring King Of Prussia PA USA;

CSL Behring King Of Prussia PA USA;

CSL Behring King Of Prussia PA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor IX (FIX) Levels in Hemophilia B Patients Receiving IDELVION [J] . Fosser C., Roberts J., Tortorici M., Journal of pharmacokinetics and pharmacodynamics . 2017 ,第Suppla期

机译：鉴定有关血友病患者的因子IX（修复）水平的有效阈值，血友病患者接受eteelvion的患者
2. Multicentre evaluation of CK CK Prest ? ? for assaying plasma levels of factor IX fused with albumin (Idelvion ? ? ) [J] . Pouplard Claire, Galinat Hubert, Ternisien Catherine, Haemophilia: the official journal of the World Federation of Hemophilia . 2019 ,第5期

机译：CK CK PERTT的多期评价？还用于测定与白蛋白融合的因子Ix的血浆水平（eteelvion？？？）
3. Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy [J] . Leebeek Frank, Meijer K., Coppens Michiel, Blood: The Journal of the American Society of Hematology . 2018 ,第NovaelaTreatmentAppr期

机译：在AMT-060（AAV5-HFIX）基因治疗治疗的严重或中度严重的血友病B中的成人减少年化血量和因子IX消费量高达2.5岁
4. Identifying risk factors for two complication types for neonatal intensive care patients (NICU) [C] . Frize, Monique, Walker, Engineering in Medicine and Biology Society, 2006 Annual International Conference of the IEEE . 2006

机译：确定新生儿重症监护患者（NICU）两种并发症类型的危险因素
5. Risk factors associated with in-hospital bleeding complications in patients undergoing pancreaticoduodenectomies. [D] . Murphy, Keith Joseph. 2016

机译：接受胰十二指肠切除术的患者与院内出血并发症相关的危险因素。
6. Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients [O] . Qiuya Lu, Likui Yang, Chandrashekhara Manithody, -1

机译：血友病患者可变出血的IX因子Gly-317变体的表达与特征
7. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A [O] . Collins, P. W., Blanchette, V. S., Fischer, K., 2009

机译：接受严重A型血友病预防性治疗的患者中与预测的VIII因子水平相关的突破性出血

Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor IX (FIX) Levels in Hemophilia B Patients Receiving IDELVION

著录项

相似文献

相关主题

期刊订阅